Advances and unanswered questions in AML: novel agents, MRD assessment, and immunotherapy

Advances and unanswered questions in AML: novel agents, MRD assessment, and immunotherapy

03:21 |

Related Videos

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

5:11

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

3:08

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

The future of CLL treatment: aiming for long-lasting remission

1:42

The future of CLL treatment: aiming for long-lasting remission

Moving away from chemoimmunotherapy and towards novel targeted agents in CLL

2:57

Moving away from chemoimmunotherapy and towards novel targeted agents in CLL

The use of outpatient cilta-cel in the treatment of multiple myeloma

1:36

The use of outpatient cilta-cel in the treatment of multiple myeloma

Frontline treatment for CLL: the changing paradigm

1:31

Frontline treatment for CLL: the changing paradigm

Early detection and interception across hematological cancers

0:44

Early detection and interception across hematological cancers

The tests that are needed to make a definitive diagnosis of CLL

2:59

The tests that are needed to make a definitive diagnosis of CLL

The use of golcadomide in combination with R-CHOP for the treatment of aggressive B-cell lymphomas

1:38

The use of golcadomide in combination with R-CHOP for the treatment of aggressive B-cell lymphomas

Treatment-free remission after second-generation TKI treatment in CML

1:01

Treatment-free remission after second-generation TKI treatment in CML

A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib

2:55

A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib

Master class in transplantation and hematology: highlights

3:40

Master class in transplantation and hematology: highlights

Mechanisms of resistance to the TKI asciminib in CML

1:16

Mechanisms of resistance to the TKI asciminib in CML

Molecular MRD as a prognostic marker for AML patients with mutated CEBPA

1:13

Molecular MRD as a prognostic marker for AML patients with mutated CEBPA

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

5:21

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

Cardiotoxicity associated with MCL-1 inhibition for R/R hematologic malignancies

2:38

Cardiotoxicity associated with MCL-1 inhibition for R/R hematologic malignancies

The new criteria for defining high-risk multiple myeloma

3:00

The new criteria for defining high-risk multiple myeloma

Challenges in developing immunotherapies for CLL compared to other hematologic malignancies

1:53

Challenges in developing immunotherapies for CLL compared to other hematologic malignancies

The role of asparaginase in the treatment of ALL

3:02

The role of asparaginase in the treatment of ALL

Exploring the biological mechanisms driving MBL progression to CLL

1:01

Exploring the biological mechanisms driving MBL progression to CLL